Aptamers for In Vivo Imaging

The Aptamer Handbook: Functional Oligonucleotides and Their Applications

Volumn , Issue , 2006, Pages 343-362

  Borkowski, Sandra ^a   Dinkelborg, Ludger M ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Applications; Aptamer handbook; Aptamers for in vivo imaging; Labeling of aptamers; Modalities and requirements; Oligonucleotides in PET imaging; Oligonucleotides in SPECT imaging

Indexed keywords

EID: 84879841681     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527608192.ch16     Document Type: Chapter

References (32)

1. Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ (1992). Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355, 564-566.
2. Boisgard R, Khnast B, Vonhoff S et al. (2005). In vivo biodistribution and pharmacokinetics of 18F-labelled Spiegelmers: a new class of oligonucleotidic radiopharmaceuticals. Eur J Nucl Med Mol Imaging 32, 470-477.
3. Charlton J, Sennello J, Smith D (1997). In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase. Chem Biol 4, 809-816.
4. Dougan H, Hobbs JB, Weitz JI, Lyster DM (1997). Synthesis and radioindination of a stannyl oligodesoxyribonucleotide. Nucleic Acids Res 25, 2897-2901.
5. Dougan H, Weitz JI, Stafford AR et al. (2003). Evaluation of DNA aptamers directed to thrombin as potential thrombus imaging agents. Nucl Med Biol 30, 61-72.
6. Duatti A (2004). In vivo imaging of oligonucleotides with nuclear tomography. Curr Drug Targets 5, 753-760.
7. Hedberg E, Langstrm B (1998). 18F-labelling of oligonucleotides using succinimido 4-[18F]fluorobenzoate. Acta Chem Scand 52, 1034-1039.
8. Hicke BJ, Stephens AW (2000). Escort aptamers: a delivery service for diagnosis and therapy. J Clin Invest 106, 923-928.
9. Hicke BJ, Marion C, Chang YF et al. (2001). Tenascin-C aptamers are generated using tumor cells and purified protein. J Biol Chem 276, 48644-48654.
10. Hicke BJ, Stephens AW, Gould T et al. Tumor targeting by an aptamer. J Nucl Med in press.
11. Hilger CS, Willi MC, Wolters M, Pieken W (1998). Synthesis of Tc-99m-labeled, modified RNA. Tetrahedron Lett 39, 9403-9406.
12. Hjelstuen OK, Tonnesen HH, Bremer PO, Verbruggen AM (1998). 3l-99mTc-labeling and biodistribution of a CAPL antisense oligonucleotide. Nucl Med Biol 25, 651-657.
13. Khnast B, Dollé F, Terrazzino S et al. (2000). General method to label antisense oligonucleotides with radioactive halogens for pharmacological and imaging studies. Bioconj Chem 11, 627-636.
14. Leppnen O, Janjic N, Carlsson MA, Pietras K, Levin M, Vargeese C, Green LS, Bergqvist D, Ostman A, Heldin CH (2000). Intimal hyperplasia recurs after removal of PDGFAB and-BB inhibition in the rat carotid artery injury model. Arterioscler Thromb Vasc Biol 20, E89-E95.
15. Lupoldt SE, Hicke BJ, Lin Y, Coffey DS (2002). Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 62, 4029-4033.
16. Mier W, Eritja R, Mohammed A et al. (2000). Preparation and evaluation of tumor targeting peptide-oligonucleotide conjugates. Bioconj Chem 11, 855-860.
17. Qin G, Zhang Y, Cao W et al. (2005). Molecular imaging of atherosclerotic plaques with technecium-99m-labelled antisense oligonucleotides. Eur J Nucl Med Mol Imaging 32, 6-14.
18. Ringquist S, Parma D (1998). Anti-L-selectin oligonucleotide ligands recognize CD62Lpositive leukocytes: binding affinity and specificity of univalent and bivalent ligands. Cytometry 33, 394-405.
19. Rohren EM, Turkington TG, Coleman RE (2004). Clinical applications of PET in oncology. Radiology 231, 305-332.
20. Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, Henninger DD, Claesson-Welsh L, Janjic N (1998). 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165. Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273, 20556-20567.
21. Schmidt KS, Borkowski S, Kurreck J et al. (2004). Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucl Acids Res 32, 5757-5765.
22. Sun X, Fang H, Li X et al. (2005). MicroPET imaging of MCF-7 tumors in mice via unr mRNA-targeted peptide nucleic acid. Bioconj Chem 16, 294-305.
23. Tavitian B (2003). In vivo imaging with oligonucleotides for diagnosis and drug development. Gut 52 (suppl IV), iv40-iv47.
24. Tavitian B, Terrazzino S, Khnast B et al. (1998). In vivo imaging of oligonucleotides with positron emission tomography. Nature Med 4, 467-471.
25. Tung CH (2000). Preparation and applications of peptide-oligonucleotide conjugates. Bioconj Chem 11, 605-618.
26. Urbain JL (1999). Oncogenes, cancer and imaging. J Nucl Med 40, 498-504.
27. Velikyan I, Lendvai G, Vlilé M et al. (2004). Microwave accelerated 68Ga-labelling of oligonucleotides. J Label Comp Radiopharm 47, 79-89.
28. von Schulthess GK, ed. (2003). Clinical Molecular Anatomic Imaging: PET, PET/CT and SPECT/CT. Philadelphia: Lippincott Williams & Wilkins.
29. White RR, Sullenger BA, Rusconi CP (2000). Developing aptamers into therapeutics. J Clin Invest 106, 929-934.
30. Wu F, Yngve U, Hedberg E, Honda M, Lu L, Eriksson B, Watanabe Y, Bergstrom M, Langstrom B (2000). Distribution of 76Brlabeled antisense oligonucleotides of different length determined ex vivo in rats. Eur J Pharm Sci 10, 179-186.
31. Younes CK, Boisgard R, Tavitian B (2002). Labelled oligonucleotides as radiopharmaceuticals: pitfalls, problems and perspectives. Curr Pharm Des 8, 1451-1466.
32. Zhang YM, Liu N, Zhu ZH, Rusckowski M, Hantowich DJ (2000). Influence of different chelators (HYNIC, MAG3 and DTPA) on tumor cell accumulation and mouse biodistribution of technecium-99m labeled to antisense DNA. Eur J Nucl Med 27, 1700-1707.